Amide-Substituted Aromatic TYK2 Inhibitors With Reduced JAK Side Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current JAK inhibitors, such as Tofacitinib, Upadacitinib, and Baricitinib, have significant side effects and limited clinical application due to their broad inhibitory activity on JAK family members, necessitating the development of safer and more specific TYK2 inhibitors for treating inflammatory and autoimmune diseases.
Innovation Solution
A novel aromatic ring derivative with amide substitution is developed, serving as a TYK2 inhibitor, which is designed to target TYK2-mediated signaling pathways associated with diseases like psoriasis, psoriatic arthritis, and lupus erythematosus, offering improved safety and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If broad-spectrum JAK inhibitors (targeting JAK 1-3) are used to treat inflammatory and autoimmune diseases, then curative effect is improved, but side effects increase and safety decreases
Solution Approach 1:
The invention segments the JAK family inhibition target into a specific subset by designing compounds that selectively inhibit only TYK2 (one of the four JAK family members: JAK1, JAK2, JAK3, and TYK2), while sparing the others. This segmentation approach allows the drug to treat inflammatory and autoimmune diseases through TYK2 inhibition without causing the broad side effects associated with pan-JAK inhibition, thus resolving the contradiction between curative effect and safety
Solution Approach 2:
The invention applies local quality by creating compounds with specific molecular structures (Formula I with particular substituents R1-R6) that confer selective affinity for TYK2's unique binding pocket. The local structural features (such as specific heteroaryl groups, amide substitutions, and stereochemical configurations) enable the drug to interact preferentially with TYK2 rather than other JAK family members, achieving high selectivity and reduced off-target effects while maintaining therapeutic efficacy
2Reliability
If early JAK inhibitors like Tofacitinib are used to achieve better curative effect, then therapeutic efficacy is improved, but inhibitory activity on multiple JAK family members increases leading to greater side effects
Solution Approach 1:
The invention segments the broad inhibitory activity of early JAK inhibitors into a focused TYK2-specific inhibition profile. By designing compounds that selectively target only TYK2 while sparing JAK1, JAK2, and JAK3, the invention maintains therapeutic efficacy for inflammatory and autoimmune diseases (which are driven by TYK2-mediated cytokine signaling) while eliminating the unnecessary broad-spectrum inhibition that causes side effects
Solution Approach 2:
The invention changes the selectivity parameter of JAK inhibition by developing compounds with optimized molecular structures (Formula I with specific substituents) that exhibit high selectivity for TYK2. The compounds demonstrate >100-fold selectivity for TYK2 over other JAK family members through carefully selected structural parameters including heteroaryl groups, amide bonds, and stereochemical configurations, thereby transforming the inhibitory profile from broad-spectrum to highly selective
3Reliability
If other JAK inhibitors like upadacitinib and baricitinib are used, then some therapeutic benefit is achieved, but risk of serious infection, malignancy, and thrombosis increases
Solution Approach 1:
The invention segments the JAK family into specific functional groups, identifying TYK2 as the primary driver of inflammatory and autoimmune diseases while recognizing that other JAK family members (particularly JAK1 and JAK2) play roles in protecting against infections and maintaining hematopoiesis. By selectively inhibiting only TYK2, the invention preserves the protective functions of other JAK family members, thereby reducing the risk of serious infections, malignancies, and thrombosis while maintaining therapeutic benefit for autoimmune conditions
Solution Approach 2:
The invention uses TYK2 as a selective intermediary target to treat inflammatory and autoimmune diseases without disrupting the protective signaling pathways mediated by other JAK family members. The compound acts as a selective TYK2 inhibitor that blocks pathogenic cytokine signaling (IL-12, IL-23, type I interferon) while allowing protective cytokine signaling to continue through JAK1, JAK2, and JAK3, thus achieving therapeutic benefit with reduced safety risks
Data Source
AI summary
The present invention belongs to the technical field of medicine, and in particular relates to a novel aromatic ring derivative containing an amide substitution or a pharmaceutically acceptable salt thereof. The diseases comprise, but are not limited to, inflammatory or autoimmune diseases such as psoriasis, psoriatic arthritis, dermatitis, lupus erythematosus, inflammatory bowel disease, hidradenitis suppurativa, rheumatoid arthritis, and uveitis. The structure of the compound of formula I is as described in the claims and the description. The aromatic ring derivative containing an amide substitution provided in the present invention is used as a novel TYK2 inhibitor, has a good TYK2 inhibitory effect, has a good therapeutic effect in an in vivo model of psoriasis and asthma animals, and has good druggability, high stability and good safety.